SCHOTT Pharma, a pioneer in pharma drug containment solutions and delivery systems, today published its results for the second quarter of the fiscal year 20251. “Despite ongoing macroeconomic uncertainties and market volatility, we continue to see strong momentum in the long-term trends shaping the pharmaceutical industry. Our strong innovations and capacity expansions drive our growth, in both the core business and the high-value solution business. We are well on track to achieve our financial targets 2025,” said Andreas Reisse, CEO of SCHOTT Pharma.
“Following a softer start into the year, increased demand for high-value solutions and our ongoing cost savings led to a strong second-quarter bottom line performance. Our investments in expanding capacities and optimising our portfolio provide a strong foundation for continued financial stability and growth,“ said Dr. Almuth Steinkühler, CFO of SCHOTT Pharma.
Strong growth in revenues; positive mix shift led to significant increase in EBITDA
Revenues in Q2 2025 reached EUR 252m, reflecting a solid increase of 8% yoy as reported or an increase of 10% at constant currencies. The main driver for this growth was the high demand for strong-margin high-value solutions (HVS), in the Drug Containment Solution (DCS) segment across the board from ready-to-use (RTU) products to specialty vials. In addition, the ongoing strong demand for glass syringes in the Drug Delivery Systems (DDS) segment compensated for a temporary weaker demand for polymer syringes.
SCHOTT Pharma’s EBITDA surged to EUR 72m, a significant increase of 63% yoy as reported. This strong increase was driven by a mix shift towards HVS and the continued execution of efficiency measures. In addition, last year’s Q2 experienced strong FX headwinds mainly from hedging totalling to 23m EUR. The FX effects in Q2 2025 were marginal. Consequently, EBITDA at constant currencies amounted to 72m EUR. EBITDA margin increased to 28.6%, which compares to a margin of 18.9% in Q2 2024. At constant currencies, the EBITDA margin in Q2 2025 stood at 28.2%. The positive impact of efficiency measures and HVS growth overcompensated the temporary underutilisation in vial and polymer syringe capacities as well as the current ramp-up costs in Hungary and Serbia. The direct impact from US tariffs is expected to be limited. SCHOTT Pharma is well on track to achieve its fiscal year guidance.
The DDS segment saw a continuous high demand for glass syringes. SCHOTT Pharma reports revenues of EUR 109m in Q2 2025, which presents an increase of 9% yoy. DDS EBITDA amounted to EUR 38m, only marginally below the very strong results from last year’s Q2. This figure includes ramp-up costs for further production capacities for prefillable glass syringes in Hungary.
In the DCS segment, revenues showed a strong 7% increase yoy to EUR 143m. This performance was specifically driven by the high demand for HVS such as sterile vials and cartridges as well as coated specialty vials. On the back of HVS growth and ongoing cost improvement measures, DCS EBITDA increased by 21% to EUR 33m and an improved margin.
Driving innovation across segments
SCHOTT Pharma continues to drive innovation with its SCHOTT TOPPAC® freeze polymer syringe, the first and only syringe on the market designed for ultra-low temperature storage at -180 °C. This product supports the safe storage of sensitive biologics, such as cell and gene therapies, advancing patient safety.
SCHOTT Pharma is also expanding its cartriQ® portfolio with the launch of a 1.5 ml RTU cartridge, the smallest sterile format in its lineup, used for the safe storage of medications like insulin, GLP-1 drugs, and hormone therapies. Designed to meet the growing demand for efficient pharmaceutical manufacturing, the new small cartridge leverages an innovative diamond-shaped nest and helps pharmaceutical companies improve efficiency, reduce costs, and accelerate time-to-market for medications.
Additionally, through the “Alliance for RTU”, SCHOTT Pharma and its partners are promoting the market adoption of RTU solutions. This strategic network aims to enhance manufacturing efficiency and patient safety and is continuously growing.
Outlook
Based on the good developments in the first half of fiscal year 2025, SCHOTT Pharma is well on track to achieve its full year guidance of revenue growth in the high single digits as well as an EBITDA margin approximately at the high level of FY 2024 (both at constant currencies).
Looking ahead, the market demand might experience some short-term volatility due to macro-economic uncertainties. However, the long-term pharma trends remain intact and will drive SCHOTT Pharma’s main growth in the long-term.
Key figures Q2 2025
Key figures H1 2025
References
-
The fiscal year runs from October to September. Q2 2025 therefore relates to the period from January 2025 to March 2025.
- CC = at constant currencies
